Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Development & Approval Process | Drugs

Development & Approval Process | Drugs

                        Clinical Data Summary Pilot Program
          Drug Development Tools | DDTs
          Guidance Documents for Drug Applications
          Laws, Regulations, Policies and Procedures for Drug Applications
          Pilot Program for the Review of Innovation and Modernization of Excipients (PRIME)


                        Drug Development Tool (DDT) Qualification Programs
          CDER Small Business & Industry Assistance (SBIA)
          Conducting Clinical Trials
          Development Resources
          Drug Approvals and Databases
          Forms & Submission Requirements
          How Drugs are Developed and Approved
          New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products
          Pharmaceutical Quality Resources Home
          Drugs
          Development & Approval Process | Drugs
          Frequently Asked Questions on Patents and ExclusivityDevelopment & Approval Process | Drugs Frequently Asked Questions on Patents and Exclusivity
  
  	
    Share
    Post
    Linkedin

    Email
    PrintExclusivity and Generic Drugs: What Does It Mean? Infographic (PDF - 470KB)
ucm606399.jpg

Exclusivity

What is the difference between patents and exclusivity?
	How long is a patent term?
	How long does an exclusivity period last?
	Why does the exclusivity expire before the patent? 
	Patent before exclusivity? 
	Why does a particular drug product only have patents? 
	Only have exclusivity? 
	Have neither?
	What information related to pediatric exclusivity is listed in the Orange Book?
	Where can I find patent and exclusivity regulations in the Code of Federal Regulations (C.F.R.)?
	How is an NDA holder notified if their application has received a period of exclusivity?Patents

When should an NDA holder submit patent information?
	What is a patent submission date?
	Why doesn’t the Orange Book include patent submission dates for most records?
	How can an NDA holder request a patent submission date error correction?
	How should an NDA holder correct or request removal of patent information?
	Should an NDA holder submit patent information when seeking approval of a supplement?
	When may an NDA holder amend the description of the approved method(s) of use claimed by the patent?
	What actions must a pending ANDA or 505(b)(2) applicant take if patent information is untimely filed?
	Is there a specific format in which patent information needs to be submitted to the agency?
	To which submissions does the final rule apply?
	Does previously submitted patent information have to be re-submitted on the new Forms FDA 3542 and 3542a?
	Who do I contact with specific questions regarding what patents are eligible for listing in the Orange Book?**Orange Book Frequently Asked Questions**

**1. What is the difference between patents and exclusivity?**
Patents and exclusivity work in a similar fashion but are distinct from one another and governed by different statutes. Patents are a property right granted by the United States Patent and Trademark Office anytime during the development of a drug and can encompass a wide range of claims.  Exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements.  A new drug application (NDA) or abbreviated new drug application (ANDA) holder is eligible for exclusivity if statutory requirements are met.  See 21 C.F.R. 314.108, 316.31, 316.34 and sections 505A, 505E, and 505(j)(5)(B)(iv) of the FD&C Act.  Periods of exclusivity and patent terms may or may not run concurrently. Exclusivity was designed to promote a balance between new drug innovation and greater public access to drugs that result from generic drug competition.

Back to Top

**2. How long is a patent term?**
Patent terms are set by statute.  Currently, the term of a new patent is 20 years from the date on which the application for the patent was filed in the United States.  Many other factors can affect the duration of a patent.

Back to Top

**3. How long does an exclusivity period last?**
It depends on what type of exclusivity is at issue.

Orphan Drug Exclusivity (ODE) – 7 years
	New Chemical Entity Exclusivity (NCE) – 5 years
	Generating Antibiotic Incentives Now (GAIN) Exclusivity– 5 years added to certain exclusivities
	New Clinical Investigation Exclusivity – 3 years
	Pediatric Exclusivity (PED) – 6 months added to existing Patents/Exclusivity
	Patent Challenge (PC) – 180 days (this exclusivity is for ANDAs only)
	Competitive Generic Therapy (CGT) - 180 days (this exclusivity is for ANDAs only)See 21 C.F.R. 314.108, 316.31, 316.34 and sections 505A, 505E, 505(j)(5)(B)(iv), and Section 505(j)(5)(B)(v) of the FD&C Act.

Back to Top

**4. Why does the exclusivity expire before the patent?
Patent before exclusivity?
Why does a particular drug product only have patents?
Only have exclusivity?
Have neither?**
Patents and exclusivity apply to drugs in different ways.  Patents can be issued or expire at any time regardless of the drug’s approval status.  Exclusivity attaches upon approval of a drug product if the statutory requirements are met.  Some drugs have both patent and exclusivity protection while others have just one or neither.  Patents and exclusivity may or may not run concurrently and may or may not cover the same aspects of the drug product. Patents and exclusivities that have expired are removed from the Orange Book.

Back to Top

**5. What information related to pediatric exclusivity is listed in the Orange Book?**
When pediatric exclusivity is obtained, a 6-month period of exclusivity is added to all existing patents and exclusivity on all applications held by the sponsor for that active moiety.  Pediatric exclusivity does not stand alone, but attaches to existing exclusivity.  When pediatric exclusivity attaches, in the patent column of the Orange Book, the patent is shown twice—once with the original patent expiration date and a second time reflecting the six month period of pediatric exclusivity linked to that particular patent.  Related information can be found on the web page Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act: Frequently Asked Questions on Pediatric Exclusivity (505A), The Pediatric "Rule," and their Interaction

Back to Top

**6. Where can I find patent and exclusivity regulations in the Code of Federal Regulations (C.F.R.)?******

See 21 C.F.R. 314.50       Content and format of an NDA
See 21 C.F.R. 314.52       Notice of certification of invalidity, unenforceability, or noninfringement of a patent
See 21 C.F.R. 314.53       Submission of patent information
See 21 C.F.R. 314.54       Procedure for submission of a 505(b)(2) application requiring investigations for approval of a new indication for, or other change from, a listed drug 
See 21 C.F.R. 314.60       Amendments to an unapproved NDA, supplement, or resubmission
See 21 C.F.R. 314.70       Supplements and other changes to an approved NDA
See 21 C.F.R. 314.94       Content and format of an ANDA
See 21 C.F.R. 314.95       Notice of certification of invalidity, unenforceability, or noninfringement of a patent
See 21 C.F.R. 314.96       Amendments to an unapproved ANDA
See 21 C.F.R. 314.97       Supplements and other changes to an ANDA
See 21 C.F.R. 314.101     Filing an NDA and receiving an ANDA                             
See 21 C.F.R. 314.107     Date of approval of a 505(b)(2) application or ANDA
See 21 C.F.R. 314.108     New drug product exclusivity
See 21 C.F.R. 316.31       Scope of orphan-drug exclusive approval
See 21 C.F.R. 316.34       FDA recognition of exclusive approval

***Code of Federal Regulations*** on the Government Publishing Office web site.Back to Top

**7. How is an NDA holder notified if their application has received a period of exclusivity?**

No letters are sent to the application holder to indicate that a period of exclusivity has attached to their application. The posting of exclusivity information in the Orange Book is the official vehicle for dissemination of this information.

Back to Top**8. When should an NDA holder submit patent information?**
Patent information is required to be submitted with all new drug applications (NDAs) and certain supplemental applications (sNDAs) on Form FDA 3542a at the time of submission of the NDA or sNDA.  Patent information for listing in the Orange Book must be submitted on Form FDA 3542 within 30 days following approval of an NDA or supplemental application. For patents issued after approval of the NDA or supplement, the NDA holder must submit the required patent information within 30 days of the issuance of the patent for it to be considered timely filed.  If the NDA holder timely submits the required patent information, but FDA notifies the NDA holder that its Form FDA 3542 is incomplete or shows that the patent is not eligible for listing, the NDA holder must submit an acceptable Form FDA 3542 within 15 days of FDA’s notification to be considered timely filed as of the date of the original submission of patent information.  New patent information may still be submitted after 30 days of the issuance of the patent, but such information is not considered timely filed.

Back to Top

**9. What is a patent submission date?**
A patent submission date is the date on which the FDA receives patent information from the new drug application (NDA) holder. See 21 C.F.R. 314.53(d)(5).

Back to Top

**10. Why doesn’t the Orange Book include patent submission dates for most records?**
The FDA began patent submission date data collection in 2013. The October 2016 final rule “Abbreviated New Drug Applications and 505(b)(2) Applications” states, “FDA intends to list the date of submission of patents and patent information in the Orange Book on a prospective basis beginning as soon as is practicable after the effective date of this rule.” The Orange Book will now publish patent submission dates for all new records going forward.

Back to Top

**11. How can an NDA holder request a patent submission date error correction?**
NDA holders should email error correction requests, including justification for the request to:orangebook@fda.hhs.gov.

Requests will be considered on a case by case basis and, if accurate, will be updated in the Orange Book as soon as is practicable.

Back to Top

**12. How should an NDA holder correct or request removal of patent information?**
An NDA holder must submit a correction or change to previously submitted patent information on a new Form FDA 3542.  For changes to descriptions of approved methods of use, see question 14.

If an NDA holder determines that a patent or patent claim no longer meets the requirements for listing, the NDA holder must promptly notify FDA to amend the patent information or withdraw the patent or patent information and request that the patent or patent information be removed from the list.  The NDA holder seeking to withdraw a patent must submit to its NDA a statement containing the NDA number to which the request applies, each product(s) approved in the NDA to which the request applies, and the patent number, and identify the submission as “Time Sensitive Patent Information.” If the NDA holder is required by court order to amend patent information or withdraw a patent from the list, it must submit an amendment to its NDA that includes a copy of the order, within 14 days of the date the order was entered.  In addition, the NDA holder must submit a correction to the expiration date of the patent on Form FDA 3542 within 30 days after the grant of patent term extension.

Back to Top

**13. Should an NDA holder submit patent information when seeking approval of a supplement?**
An NDA holder must submit patent information when it seeks approval of a supplement to add or change the dosage form or route of administration, to add or change the strength or to change the drug product from prescription use to over-the-counter use.

For supplements that seek approval for other changes (for example, to change the formulation, to add a new indication or other condition of use, or to make any other patented change regarding the drug substance, drug product, or any method of use), the requirements for submitting patent information depend on whether the existing patent information in the Orange Book for the original NDA continues to claim the changed product:

If one or more patents, for which information was properly submitted for the product approved in the original NDA, claim the changed product, then the applicant is not required to resubmit this patent information, and FDA will continue to list the patent information.
	If one or more patents, for which information was properly submitted for the product approved in the original NDA, no longer claim the changed product, the applicant must submit a request to remove the listed patent information at the time of the approval of the supplement.
	If one or more patents, for which information was not previously submitted, claim the changed product, the applicant must submit the patent information required under 314.53(c).The NDA holder also must submit patent information for any supplement if the description of the patented method of use in the Orange Book would change upon approval of the supplement.Back to Top

**14. When may an NDA holder amend the description of the approved method(s) of use claimed by the patent?**
An amendment to the description of approved method(s) of use claimed by the patent will be considered timely if it is submitted within 30 days of: (1) patent issuance, (2) approval of a corresponding change to product labeling, or (3) a decision by the U.S. Patent and Trademark Office or a Federal court that is specific to the patent and alters the construction of a method-of-use claim(s) of the patent (and the amendment contains a copy of the decision).  Outside of these circumstances and except as provided in the patent listing dispute regulation (21 CFR 314.53(f)(1)), an amendment to the description of the approved method(s) of use claimed by the patent will not be considered timely filed.

If the amendment to the description of the approved method(s) of use claimed by the patent is filed within an acceptable time frame but is incomplete or shows that the patent is not eligible for listing, the NDA holder must submit an acceptable Form FDA 3542 within 15 days of FDA’s notification to be considered timely filed as of the date of the submission of amended patent information.

Back to Top

**15. What actions must a pending ANDA or 505(b)(2) applicant take if patent information is untimely filed?**
If patent information is untimely filed, generally a previously submitted ANDA or 505(b)(2) applicant is not required to submit a patent certification or statement to address the patent or patent information that is late-listed with respect to the pending ANDA or 505(b)(2) application.

Back to Top

**16. Is there a specific format in which patent information needs to be submitted to the agency?**
If the NDA applicant is submitting patent information with an original NDA, an amendment, or a supplement prior to approval, use Form FDA 3542a. If the NDA holder is submitting information on a patent that claims an approved drug or an approved method of using the drug after approval of an NDA or supplement, use Form FDA 3542. The agency will not list or publish patent information in the Orange Book if it is not provided on Form FDA 3542.

Back to Top

**17. To which submissions does the final rule apply?**
The effective date of the final rule on “Abbreviated New Drug Applications and 505(b)(2) Applications” applies to any submission received by FDA on or made after December 5, 2016, the effective date of the rule, including any changes to previously submitted patent information.

Back to Top

**18. Does previously submitted patent information have to be re-submitted on the new Forms FDA 3542 and 3542a?**
No.  While any patent information submitted after the effective date of the final rule must be submitted in a manner consistent with the final rule, including use of the new forms, NDA holders and applicants are not required to re-submit patent information previously submitted on a prior version of the form.

Back to Top

**19. Who do I contact with specific questions regarding what patents are eligible for listing in the Orange Book?**
FDA’s patent listing role is ministerial.  Generally, we will not respond to specific questions regarding the eligibility of patents for listing.

Back to Top

Resources For You

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
	FAQs on The Orange Book
	CDER Exclusivity Board

                                                                                  Content current as of:
      02/05/2020Development & Approval Process | Drugs

          
                        Clinical Data Summary Pilot Program
          Drug Development Tools | DDTs
          Guidance Documents for Drug Applications
          Laws, Regulations, Policies and Procedures for Drug Applications
          Pilot Program for the Review of Innovation and Modernization of Excipients (PRIME)


                        Drug Development Tool (DDT) Qualification Programs
          CDER Small Business & Industry Assistance (SBIA)
          Conducting Clinical Trials
          Development Resources
          Drug Approvals and Databases
          Forms & Submission Requirements
          How Drugs are Developed and Approved
          New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products
          Pharmaceutical Quality Resources
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop